Discover B2B leads for Pharmaceuticals industry
Identify and research relevant prospects for B2B lead generation on Pharmaceuticals sector. Find their verified contact details to reach out to them, nurture and convert them into paying clients. Streamline the process of filtering B2B prospects by searching for bisinesses based on their specifics like location, name or category.
Businesses
Found 12 in our database
Found 131 in our records

HQ: Cambridge, Massachusetts, United States
Moderna Therapeutics is a biotechnology company thShow more...at specializes in drug discovery and drug development based on messenger RNA.
HQ: Cambridge, Massachusetts, United States
Specialized In: Biotechnology, Healthcare & Medical, Pharmaceuticals
Business Type: Public
Employees: 1001-5000
Rounds: Post-IPO Equity
Last Investment Activity: Mar 15, 2024
Founded Date: 2010
Number of Exits: 3
Company Type: For Profit
Stock Symbol: NASDAQ:MRNA
Operating Status: Active
Investor Type: Investment Bank
Main email format: sarah.smith@modernatx.com (100.0%)
-
Tatiana Novobrantseva
Chief Scientific Officer, Immuno-Oncology Research
t*******************a@modernatx.com
-
Juan Andres
Senior Vice President Technical Development, Manufacturing and Quality
j*********s@modernatx.com
-
Nidal El Assi
Associate Director Of Lab Operations
n********i@modernatx.com
-
Lavina Talukdar
l*************r@modernatx.com
-
Shannon Thyme Klinger
Chief Legal Officer at Moderna
s*************r@modernatx.com
-
Gamal Elfatarany
g**************y@modernatx.com
-
Unclassified inbox
WeCare@modernatx.com
-
Unclassified inbox
Grace.Chen@modernatx.com
-
General Inquiries
info@modernatx.com

HQ: Temple City, California, United States
Fulgent Therapeutics, LLC is a pharmaceutical compShow more...any focusing on developing and commercializing innovative cancer therapeutics.
HQ: Temple City, California, United States
Specialized In: Biotechnology, Healthcare & Medical, Pharmaceuticals, Hospitals & Clinics
Business Type: Public
Employees: 1001-5000
Rounds: Venture - Series Unknown
Last Investment Activity: Nov 7, 2022
Founded Date: 2011
Company Type: For Profit
Stock Symbol: NASDAQ:FLGT
Operating Status: Active
Main email format: ssmith@fulgentgenetics.com (69.2%)
-
James Liu
Director of System Architecture,Enterprise Systems Architect
j**u@fulgentgenetics.com
-
Ming Hsieh
m*******h@fulgentgenetics.com
-
Rod Gervacio
CLS Lead
r*******o@fulgentgenetics.com
-
Spencer Young
Solutions/Software Analyst/Scientist/Engineer
s****g@fulgentgenetics.com
-
Benjamin Ramos
Talent Acquisition Specialist
b****s@fulgentgenetics.com
-
Doreen Ng
VP, Operations & Compliance | General Manager (Houston)
d******g@fulgentgenetics.com
-
Natalie Prescott
General Counsel & Chief Privacy Officer
n*******t@fulgentgenetics.com
-
Hanlin Gao
Lab Director and Chief Scientific Officer
h**o@fulgentgenetics.com
-
Paul Kim
Chief Financial Officer
p**m@fulgentgenetics.com
-
General Inquiries
info@fulgentgenetics.com
-
Customer Service
lacsupport@fulgentgenetics.com
-
Unclassified inbox
insurance@fulgentgenetics.com
-
General Inquiries
info@fulgent-therapeutics.com

HQ: New York, New York, United States
Loxo Oncology is a biopharmaceutical company focusShow more...ed on targeted cancer therapies for genetically-defined patient populations.
HQ: New York, New York, United States
Specialized In: Pharmaceuticals, Biotechnology, Healthcare & Medical, Hospitals & Clinics
Business Type: Public
Employees: 501-1000
Rounds: Post-IPO Equity
Last Investment Activity: Oct 17, 2022
Founded Date: 2013
Company Type: For Profit
Stock Symbol: NASDAQ:LOXO
Operating Status: Active
Main email format: ssmith@loxooncology.com (87.5%)
-
Ipsita Roy
Sr. Program/Project Manager
i**y@loxooncology.com
-
Nisha Nanda
Director, Clinical Science and Development
n***a@loxooncology.com
-
General Inquiries
info@loxooncology.com
-
Unclassified inbox
clinicaltrials@loxooncology.com

HQ: Cambridge, Massachusetts, United States
Genzyme Corporation (Genzyme) is a biotechnology cShow more...ompany. The Company's product and service portfolio is focused on rare genetic disease
HQ: Cambridge, Massachusetts, United States
Specialized In: Pharmaceuticals, Biotechnology
Business Type: Private
Employees: 10001+
Last Investment Activity: Jul 30, 2024
Founded Date: 1981
Number of Exits: 3
Company Type: For Profit
Operating Status: Closed
Main email format: sarah.smith@genzyme.com (100.0%)
-
Eliana Clark
Chief Technical Officer
e**********k@genzyme.com
-
Morrill Reynolds
Principal Project Manager
m**************s@genzyme.com
-
Louise Harney
louise.harney@genzyme.com
-
General Inquiries
info@genzyme.com

HQ: Cambridge, Cambridgeshire, United Kingdom
Horizon is a gene editing company that designs & eShow more...ngineers genetically-modified cells, applying them to advance human health.
HQ: Cambridge, Cambridgeshire, United Kingdom
Specialized In: Pharmaceuticals, Biotechnology, Health Diagnostics
Business Type: Public
Employees: 101-250
Rounds: Post-IPO Equity
Last Investment Activity: Feb 10, 2022
Founded Date: Jun 2007
Company Type: For Profit
Stock Symbol: LSE:HZD
Operating Status: Active
Main email format: sarah.smith@horizondiscovery.com (100.0%)
-
Jon Aviles
General Manager
j********s@horizondiscovery.com
-
Jon Nunez
Vice President , Finance
j*******z@horizondiscovery.com
-
General Inquiries
info@horizondiscovery.com
-
Sales Department
sales@horizondiscovery.com
-
Legal Department
legal@horizondiscovery.com

HQ: Fort Myers, Florida, United States
NeoGenomics is a cancer reference laboratory that Show more...provides cancer testing and partnership programs to pathologists and oncologists.
HQ: Fort Myers, Florida, United States
Specialized In: Biotechnology, Healthcare & Medical, Health Diagnostics, Pharmaceuticals
Business Type: Public
Employees: 501-1000
Rounds: Post-IPO Equity
Last Investment Activity: Mar 18, 2024
Founded Date: Oct 29, 1998
Number of Exits: 1
Company Type: For Profit
Stock Symbol: NASDAQ:NEO
Operating Status: Active
Main email format: ssmith@neogenomics.com (100.0%)
-
Unclassified inbox
aimee.bui@neogenomics.com
-
Human Resources Team
HR@neogenomics.com
-
Human Resources Team
hr@neogenomics.com

HQ: Dublin, Dublin, Ireland
Shire biotechnology company that focuses on servinShow more...g people with rare diseases.
HQ: Dublin, Dublin, Ireland
Specialized In: Pharmaceuticals, Biotechnology, Healthcare & Medical, Hospitals & Clinics, Wellness
Acquired by: Takeda
Business Type: Public
Employees: 10001+
Rounds: Venture - Series Unknown
Last Investment Activity: May 14, 2024
Founded Date: 1986
Number of Exits: 4
Company Type: For Profit
Stock Symbol: NASDAQ:SHPG
Operating Status: Closed
Main email format: ssmith@shire.com (100.0%)
-
Victor Otcheretko
v*********o@shire.com
-
General Inquiries
info@shirehousing.com
-
General Inquiries
info@shirefoods.com
-
Unclassified inbox
golf@theshirelondon.com
-
Unclassified inbox
shire@woodanilling.wa.gov.au
-
Unclassified inbox
abcdefghij@shire.com

HQ: Redwood City, California, United States
Genomic Health is a provider of genomic-based diagShow more...nostic tests that address overtreatment and optimal treatment of early-stage cancer.
HQ: Redwood City, California, United States
Specialized In: Biotechnology, Healthcare & Medical, Pharmaceuticals
Acquired by: Exact Sciences
Business Type: Delisted
Employees: 501-1000
Last Investment Activity: Oct 3, 2023
Founded Date: 2000
Number of Exits: 1
Company Type: For Profit
Stock Symbol: NASDAQ:GHDX
Operating Status: Active
Main email format: ssmith@genomichealth.com (100.0%)
-
G. Bradley Cole
COO
-
Dean L. Schorno
CFO
-
Venora Hung
Privacy Counsel
-
Kimberly J. Popovits
President, CEO & Chairman
-
rick baehner
Vice President Medical Oncology and Pathology
-
Customer Service
customerservice@genomichealth.com

HQ: Alachua, Florida, United States
AGTC is a biotechnology company conducting human cShow more...linical trials of AAV-based gene therapies for the treatment of rare diseases.
HQ: Alachua, Florida, United States
Specialized In: Biotechnology, Healthcare & Medical, Pharmaceuticals
Business Type: Public
Employees: 101-250
Rounds: Post-IPO Equity
Last Investment Activity: Nov 22, 2022
Founded Date: 1999
Company Type: For Profit
Stock Symbol: NASDAQ:AGTC
Operating Status: Active
-
Scott Koenig
Chairman of the Board of Directors
-
Sue Washer
President & CEO
-
Terence Flotte
Founder
-
R. Jude Samulski
Founder
-
Barry Byrne
Founder
-
William A. Sullivan
Chief Financial Officer
-
Mark S.Shearman
Chief Scientific Officer
-
Larry Bullock
Chief Financial Officer
-
Unclassified inbox
webmaster@agtc.com

HQ: Shenzhen, Guangdong, China
BGI Group is one of the world’s largest DNA sequenShow more...cing service providers.
HQ: Shenzhen, Guangdong, China
Specialized In: Biotechnology, Healthcare & Medical, Pharmaceuticals
Business Type: Public
Employees: 5001-10000
Rounds: Post-IPO Equity
Last Investment Activity: Aug 9, 2023
Founded Date: Nov 1999
Company Type: For Profit
Stock Symbol: SZSE:300676
Operating Status: Active
-
Huanming Yang
Co-founder
-
Yingjun Sun
Executive Vice President
-
Yongwei Zhang
Group VP, CEO of Americas Region
-
Shuang Yang
COO
-
Ye Yin
CEO
-
Jian Wang
President
-
General Inquiries
info@genomics.cn

HQ: Rockville, Maryland, United States
OriGene Technologies is a research tool company thShow more...at provides a commercial collection of full-length human cDNAs.
HQ: Rockville, Maryland, United States
Specialized In: Biotechnology, Medical Devices, Pharmaceuticals
Business Type: Private
Employees: 501-1000
Rounds: Venture - Series Unknown
Last Investment Activity: May 17, 2024
Founded Date: 1996
Number of Exits: 1
Company Type: For Profit
Operating Status: Active
-
Krishnan Allampallam
Marketing Director
-
Wei-Wu He
Founder and CEO
-
Unclassified inbox
businessdev@origene.com

HQ: Tokyo, Tokyo, Japan
AnGes is a biopharmaceutical company with a missioShow more...n to provide patients, especially those suffering from disease.
HQ: Tokyo, Tokyo, Japan
Specialized In: Pharmaceuticals, Biotechnology, Healthcare & Medical
Business Type: Public
Employees: 101-250
Rounds: Seed
Last Investment Activity: Jan 18, 2024
Founded Date: Dec 17, 1999
Number of Exits: 1
Company Type: For Profit
Stock Symbol: TYO:4563
Operating Status: Active
-
EI Yamada
President & CEO
-
Andy G. Hinson
Senior Director of Clinical Development
-
General Inquiries
info@anges.co.jp
- «
- 1
- »
We’re in beta testing! Sign up for free to unlock all the information on this page — no credit card required.